6 January 2019 – Walder Wyss advises FC Capital Fund I, L.P., Shanghai, as investor in connection with Cellestia's recent financing round. Cellestia was founded in 2014 as a spin-off from EPFL (Ecole Polytechnique Fédérale de Lausanne). Its pipeline including lead candidate, oral small molecule CB-103 is based on proprietary know-how and more than two decades of research at Swiss Institute for Experimental Cancer Research (ISREC) at EPFL.

The Walder Wyss team included Alexander Gutmans (Partner, Corporate, Venture Capital), Stefano Codoni (Partner, IP Life Sciences), Robert von Rosen (Partner, Corporate M&A), Jessica Aeschbach Flórez (Associate, Corporate) as well as Vanessa C. Haubensak (Associate, Corporate).